Chronic fatigue syndrome: A disorder of central cholinergic transmission

Journal of Chronic Fatigue Syndrome

Volumn 3, Issue 1, 1997, Pages 3-16

  Chaudhuri, A ^a   Majeed, T ^a   Dinan, T ^a,b   Behan, P O ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; GROWTH HORMONE; ORGANOPHOSPHATE; PYRIDOSTIGMINE;

ADULT; ARTICLE; CHOLINERGIC TRANSMISSION; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; LONG TERM EXPOSURE; MALE; ORAL DRUG ADMINISTRATION; PROVOCATION TEST; REM SLEEP; SLEEP DISORDER;

EID: 0031017638     PISSN: 10573321     EISSN: None     Source Type: Journal    
DOI: 10.1300/J092v03n01_02     Document Type: Article

References (39)

1. Behan PO & Behan WMH. Postviral fatigue syndrome. CRC Crit Rev Neurobiol 1988; 4(2): 157-158.
2. MacAlpine D, Lumsden CD & Acheson D. Multiple sclerosis, a reappraisal. 2nd Ed. Edinburgh & London: Churchill Livingstone, 1972: 115 & 258.
3. Marsden CD & Parkes JD. "On and off" variability and response swings in Parkinson's Disease. In: Rose FC & Capildeo R., eds. Research progress in Parkinson's Disease. London: Pitman Books Ltd., 1981.
4. MacKenzie TB, Robiner WN & Knopman DS. Differences between patient and family assessments of depression in Alzheimer's disease. Am J of Psych 1989; 146(9):1174-8.
5. Bruno RL, Sapolsky R, Zimmerman JR & Frick NM. The pathophysiology of post-polio fatigue. Ann NY Acad Sci 1995; 753:257-275.
6. Dinan RD & Mobayed M. Treatment resistance of post head injury depression. A preliminary study of amitriptyline response. Acta Psychiatr Scand 1992; 85:292-294.
7. Whelton C, Salit J & Moldofsky H. Sleep, Epstein Barr virus infection, musculoskeletal pain and depressive symptoms in chronic fatigue syndrome. J Rheumatol 1992: 19; 939-943.
8. Wager S, Robinson D, Goetz R, Nunes E, Gully R & Quitkin, F. Cholinergic REM sleep induction in atypical depression. Bio Psychiat 1990; 27: 441-446.
9. Berger M, Lund R, Bronisch T & von Zerssen D. REM latency in neurotic and endognous depression and the cholinergic REM induction test. Psychiat Res 1983; 10:113-123.
10. Gillin JC, Sitaram N & Mendelson WB. Acetylcholine, sleep and depression. Hum Neurobiol 1982; 1:211-219.
11. Sitaram N, Wyatt RJ, Dawson S & Gillin JC. REM sleep induction by physostigmine infusion during sleep. Science 1976; 191:1281-1283.
12. Rowantree DW, Nevin S & Wilson A. The effects of disopropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol Neurosurg Psychiat. 1950; 13: 47-59.
13. Gershon S & Shaw FH. Psychiatric sequelae of chronic exposure to organophosphorus insecticides. Lancet 1961; i: 1371-1374.
14. Hobson JA &, Steraide M. Neuronal basis of behavioural state control. In: Mountvastle VB, Bloom FE, Geiger SR, eds. Handbook of Physiology, Bethesda, Md, American Physiological Society 1986; 4:701-823.
15. Hobson JA, McCarley RW & Wyzinski PW. Sleep cycle oscillation: Reciprocal discharge by two brainstern neuronal groups. Science 1975; 189:55-58.
16. Vivaldi E, McCarley RW, & Hobson JA. Evocation of desynchronised sleep signs by chemical microstimulation of the pontine brain stem. In: Hobson JA & Brazier MAB, eds. The reticular formation revisited. New York, Raven Press, 1980, 513-529.
17. Hobson JA, Lydic R & Baghdoyan HA. Evolving concepts of sleep cycle generation: From brain centers to neuronal populations. Behav Brain Sci 1986; 9: 371-448.
18. Janowsky DS, El-Yousef MK, Davis JM & Sekerke JH. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972; ii: 632-635.
19. Papazian O. Rapid eye movement sleep alteration in myasthenia gravis. Neurology 1976; 26:311-316.
20. Behan PO. Chronic fatigue syndrome as a delayed reaction to chronic low dose organophospate exposure. Journal of Nutritional Medicine 1996 (in press).
21. DeFraites RF, Wanat ER, Norwood AE, Williams S, Cowan D & Callahan T. Investigation of a suspected outbreak of an unknown disease among veterans of Operation Desert Shield/Storm, 123rd Army Reserve Command, Fort Benjamin Harrison, Indiana, April, 1992. Washington, DC: Epidemiology Consultant Service, Division of Preventative Medicine, Walter Reed Army Institute of Research; 1992.
22. Beal, P. Gulf illness. BMJ. 1994; 308:1574.
23. Bushnell PJ, Kelly KL & Ward TR. Repeated inhibition of cholinesterase by chlorphyrifos in rats: behavioural, neurochemical and pharmacological indices of tolerance. J Pharma & Exper Therap. 1994; 270(1): 15-25.
24. Chaudhuri A, Watson W & Behan PO. Arguments in defence of the ionophore theory as the cause of chronic fatigue syndrome. In: Chronic Fatigue Syndrome: a comprehensive approach to its definition and study. 1996 (in press ).
25. Fukada K, Straus SE, Hickie I, Sharpe CM et al. and the International Chronic Fatigue Syndrome Study Group. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953-959.
26. Cordido F, Casaneuva FF & Dieguez C. Cholinergic receptor activation by pyridostigmine restores GH responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity. J Clin Endocrin & Metab 1989; 68: 290-293.
27. O'Keane V, O'Flynn K, Lucey J & Dinan TG. Pyridostigmine-induced growth hormone responses in healthy and depressed subjects: evidence for cholinergic supersensitivity in depression. Psychol Med 1992; 92:55-60.
28. Guistina A, Bossoni S, Climini A, Pizzagalto G, Romanelli G & Wehrenberg WB. Impaired growth hormone (GH) responses to pyridostigmine in type 1 diabetic patients with exaggerated GHRH-GH-stimulated GH secretion. J Clin Endocrin & Metab 1990; 71: 1486-1490.
29. Martin JB & Reichlin S. Neuropharmacology of anterior pituitary regulation. In: Clinical Neuroendocrinology, Edition 2. Philadelphia: FA Davis Company.
30. Cordido F, Dieguez C & Casaneuva FF. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone response to growth hormone releasing hormone in the rat: evidence for mediation by somatostatin. J Clin Endocrin & Metab 1990; 70: 1361-1370.
31. Locatelli V, Torsello A, Redaelli E, Ghigo F, Massara F & Muller EE. Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone releasing hormone in the rat: evidence for mediation by somatostatin. J Endocrin 1986; 111:271-278.
32. Risch SC, Cohen PM & Janowsky DS. Physostigmine induction of depressive symptomatology in normal human subjects. J Psych Res 1981; 4: 89-94.
33. O'Keane V & Dinan TG. Sex steroid priming effects in growth hormone response to pyridostigmine throughout the menstrual cycle. J Clin Endocrinol Metab. 1992; 75: 11-14.
34. Casaneuva FF, Belti R, Cella SG, Muller EE & Mantegazza P. Effect of agonists and antagonists of cholinergic neurotransmission on growth hormone release in the dog. Acta Endocrinol 1983; 103:15-20.
35. Mendeleson WB, Sitaram N, Wyatt RJ & Gillin JC. Methoscopolamine inhibition of sleep related growth hormone secretion: Evidence for a cholinergic secretory mechanism. J Clin Investigation 1978; 61(8): 1683-1690.
36. Ross RJ, Tsagarakiss S, Grossman A et at. GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH. Clin Endocrinol (Oxf) 1987; 27:727-733.
37. Snorrason E, Geirsson A & Stefansson K. Trial of a selective acetylcholinesterase inhibtor, galanthamine hydrobromide, in the treatment of chronic fatigue syndrome. Journal of Chronic Fatigue Syndrome 1996; 2(2/3): 35-54.
38. Engel AL, Lambert EH & Santa T. Study of longterm anticholinesterase therapy. Effects on neuromuscular transmission and motor end plate fine structure. Neurology 1993; 23:1273-1287.
39. Bou-Holaigah I, Rowe PC, Kan J & Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995; 274(12): 961-967.